XSTOELN
Market cap1mUSD
Dec 23, Last price
1.03SEK
1D
0.98%
1Q
-0.96%
Jan 2017
-96.71%
IPO
-99.40%
Name
Ellen AB
Chart & Performance
Profile
Ellen AB (publ), a biotech company, develops and sells self-care products for women's intimate health. It offers ellen Probiotic Tampon products that supply probiotic lactic acid bacteria to the vagina while simultaneously offering sanitary protection; and ellen Probiotic Intimate Crème, a moisturizing intimate cream that acts as a protective barrier for skin and mucous membranes. The company also provides ellen pH-Control, a medical device, which is used to measure the vaginal pH at home; and ellen Sport Tampong/Aqua Block, which is designed to prevent chlorinated or contaminated water from seeping into the vagina while swimming or in other water activities. In addition, it offers LN Intimate Cleansing Foam to clean intimate areas, as well as used as a shaving cream for intimate grooming; LN Intimate Deo, a softening intimate deodorant formulated with lactic acid to promote a healthy vaginal flora and vaginal pH; and LN After Shave & Wax Gel that soothes the skin after shaving or waxing intimate areas or other parts of body. It operates in France, Belgium, Germany, Switzerland, Austria, Scandinavia, and other countries. The company sells its products through distributors and retailers; and through online in Scandinavia. Ellen AB (publ) was founded in 2000 and is headquartered in Stockholm, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 25,587 7.03% | 23,907 27.16% | 18,800 0.95% | |||||||
Cost of revenue | 12,507 | 22,933 | 18,535 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 13,080 | 974 | 265 | |||||||
NOPBT Margin | 51.12% | 4.07% | 1.41% | |||||||
Operating Taxes | 41 | (128) | ||||||||
Tax Rate | 4.22% | |||||||||
NOPAT | 13,080 | 933 | 393 | |||||||
Net income | (3,043) -36.71% | (4,808) -14.10% | (5,597) -27.90% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 6,615 | |||||||||
BB yield | ||||||||||
Debt | ||||||||||
Debt current | (98) | |||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | (1) | 2,094 | ||||||||
Net debt | (1,147) | (830) | (5,764) | |||||||
Cash flow | ||||||||||
Cash from operating activities | (3,960) | (4,824) | (5,153) | |||||||
CAPEX | (5) | (13) | (10) | |||||||
Cash from investing activities | (5) | (13) | (10) | |||||||
Cash from financing activities | 4,282 | 1,500 | ||||||||
FCF | 10,462 | 760 | 888 | |||||||
Balance | ||||||||||
Cash | 1,147 | 830 | 5,667 | |||||||
Long term investments | ||||||||||
Excess cash | 4,727 | |||||||||
Stockholders' equity | 1,300 | 3,039 | 7,806 | |||||||
Invested Capital | 5,779 | 3,040 | 2,982 | |||||||
ROIC | 296.65% | 30.97% | 5.17% | |||||||
ROCE | 226.34% | 32.03% | 3.44% | |||||||
EV | ||||||||||
Common stock shares outstanding | 8,456 | 5,820 | 5,820 | |||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | 13,105 | 1,007 | 331 | |||||||
EV/EBITDA | ||||||||||
Interest | 68 | 41 | ||||||||
Interest/NOPBT | 0.52% | 4.22% |